

# Behandlung von ablationsrefraktären VTs

**Arash Arya**

Herzzentrum Leipzig - Universitätsklinik

HERZZENTRUM  
LEIPZIG



# Conflict of Interests

NONE

# When is a VT refractory to ablation?

It is important to emphasize that after an initial failed endocardial or epicardial ablation, a repeat standard ablation can often be successful, suggesting that the most common reason for initial failure is **failure of mapping** or **inadequate lesion creation**.

In structural heart disease–related VT, ablation fails to abolish the clinical VTs in 5% to 10% in ischemic cardiomyopathy and 11% to 24% in NICM. \*


\* Circ Arrhythm Electrophysiol. 2017;10:e003676

**Table 1. Reasons for Acute Failure With Contemporary Catheter Ablation Techniques**


| Reasons for Acute Failure                              |                                                                                                                                                                                                                            |
|--------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Suboptimal previous endocardial or epicardial ablation |                                                                                                                                                                                                                            |
| Nonendocardial VA origin but inaccessible epicardium   |                                                                                                                                                                                                                            |
| Previous cardiac surgery                               |                                                                                                                                                                                                                            |
| Previous pericarditis                                  |                                                                                                                                                                                                                            |
| Failed attempt at epicardial access                    |                                                                                                                                                                                                                            |
| Intramural substrate                                   | Anatomic barriers prohibiting lesion formation                                                                                                                                                                             |
| Septal                                                 | Prominent trabeculations (eg, right ventricle)                                                                                                                                                                             |
| Free wall                                              | Epicardial fat (eg, LV summit)                                                                                                                                                                                             |
| VA origin in close proximity to critical structures    | Suspected nonendocardial VA origin, but epicardial access not undertaken because of anticipated cardiac surgery for other conditions, such as valve replacement or LVAD insertion, where VA surgery will also be performed |
| Endocardial: His bundle                                | Acute complications                                                                                                                                                                                                        |
| Epicardial: phrenic nerve, coronary arteries           | Ventricular perforation and tamponade                                                                                                                                                                                      |
| Inability to deliver adequate energy to VA target site | Other catastrophic complications (eg, refractory cardiogenic shock, stroke, electromechanical dissociation)                                                                                                                |
| Great cardiac vein or anterior interventricular vein   |                                                                                                                                                                                                                            |





# Anatomical Considerations






Substrate Mapping





PM Correlation Mapping










**Epicardial VT  
LVAD**

**LV Left Lateral**



| Surgical approaches <sup>7,35,36</sup> |                                                                                                           |                                                                                                                                       |                                                                                             |                                                                                              |
|----------------------------------------|-----------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| Epicardial window                      | When epicardial target suspected but percutaneous pericardial access not possible                         | Allows access to LV inferior wall and apex, but access may be limited                                                                 | Risk of bleeding because of lysis of adhesions if necessary                                 | Careful preprocedural planning with imaging, 3D mapping needed to determine optimal approach |
|                                        |                                                                                                           |                                                                                                                                       | Difficult to access anterior or lateral LV from subxiphoid approach if adhesions present    |                                                                                              |
| Thoractomy/median sternotomy           | Usually a last resort therapy or “no access” ventricles; or when other cardiac surgical indication exists | Preferred for anterior or lateral LV targets                                                                                          | Complications in 17% to 36% in a high-risk population                                       |                                                                                              |
|                                        |                                                                                                           | May allow access to entire heart to address more complex substrates or when mobilization of phrenic or coronaries needed to target VA | Noninducibility or nonsustainability of ventricular tachycardia can limit operative mapping |                                                                                              |
|                                        |                                                                                                           | Can address other surgical needs (eg, revascularization, valve replacement, LVAD replacement)                                         | Usually limited intraoperative 3D mapping options                                           |                                                                                              |
|                                        |                                                                                                           | 49% to 67% VA-free survival when used as a last resort in contemporary series                                                         |                                                                                             |                                                                                              |
|                                        |                                                                                                           | Significant ↓ VA burden                                                                                                               |                                                                                             |                                                                                              |



# Interventional Options:

Half-Saline Irrigation

Bipolar Ablation

Needle Ablation



Alcohol Ablation

Surgical Cardiac Sympathetic Denervation/RSD

New catheter design (HPSD)/ energy sources (HIFU)


**Radioablation**

In the absence of any randomized data, the **choice** and **sequence of alternative** interventional techniques are heavily influenced by institutional experience and preferences.







# Bipolar Ablation:




Heart Rhythm 2012;9:1932–1941




|                   | Endo Lesion Volume (ml) | Epi Lesion Volume (ml) | Combined Lesion Volume (ml) |
|-------------------|-------------------------|------------------------|-----------------------------|
| Unipolar          | 260.7±46.5              | 263.0±27.7             | 523.7±47.8                  |
| Bipolar 20mm      | 274.0±40.5              | 250.9±46.4             | 524.9±65.3                  |
| Bipolar 15mm      | 379.4±63.4              | 350.2±45.4             | 729.6±64.9                  |
| 20mm vs. Unipolar | p = 0.242               | p = 0.227              | p = 0.934                   |
| 15mm vs. Unipolar | p < 0.001               | p < 0.001              | p < 0.001                   |

[Heart Rhythm](#). 2016 Nov;13(11):2161-2171



# Bipolar Ablation:



# Bipolar Ablation:





# Needle Ablation:





# Transcoronary Ethanol Ablation:

In a series of 42 patients (19 with ischemic, 22 with nonischemic, and 1 with no structural heart disease) target sites were septal in 74%, aortic-mitral continuity or the outflow tracts in 9% and other non-septal sites in 23% of patients.





**Table 1**  
Cases series on ventricular tachycardia alcohol ablation

| Author, Year                                     | N  | Age (y) | ICM  | Acute Success                 | Complications                                         | Follow-up  | Recurrence |
|--------------------------------------------------|----|---------|------|-------------------------------|-------------------------------------------------------|------------|------------|
| Brugada et al, <sup>5</sup><br>1989              | 3  | 56 ± 10 | 100% | 100%                          | 33% (CHB)                                             | 1–6 mo     | 33%        |
| Dailey et al, <sup>6</sup><br>1992               | 4  | NA      | 100% | 100%                          | 25% (CHB)                                             | 4–25 mo    | 50%        |
| Kay et al, <sup>7</sup><br>1992                  | 10 | 62 ± 12 | 100% | 90% any VT                    | 40% (CHB)                                             | 372 d      | 50%        |
| Nellens et al, <sup>8</sup><br>1992              | 10 | NA      | 100% | 100%                          | NA                                                    | 2–44 mo    | 14%        |
| Segal et al, <sup>2</sup><br>2007                | 5  | 70 ± 4  | 80%  | 100%                          | 0%                                                    | 19 ± 17 mo | 0%         |
| Sacher et al, <sup>9</sup><br>2008               | 9  | 55 ± 9  | 67%  | 56% any VT<br>89% clinical VT | 33% (1 severe<br>hypotension; 2<br>groin<br>hematoma) | 29 ± 23 mo | 33%        |
| Steven et al, <sup>10</sup><br>2009 <sup>a</sup> | 3  | NA      | NA   | 100%                          | 0%                                                    | NA         | NA         |
| Tokuda et al, <sup>11</sup><br>2011              | 22 | 63 ± 13 | 52%  | 46% any VT<br>82% clinical VT | 38% (CHB)                                             | 16 d       | 64%        |
| Baher et al, <sup>3</sup><br>2012 <sup>b</sup>   | 2  | ~ 67    | 0%   | 100% clinical VT              | 50% (pericarditis)                                    | 5 mo       | 0%         |

*Abbreviations:* CHB, complete heart block; ICM, ischemic cardiomyopathy; N, number; NA, not available.

<sup>a</sup> Part of a case series on VT originating from the aortomitral continuity in structural heart disease.

<sup>b</sup> Retrograde TCEA.

# Surgical Cardiac Sympathetic Denervation:

Cardiac sympathetic denervation in patients with refractory ventricular arrhythmias or electrical storm:  
Intermediate and long-term follow-up


Heart Rhythm 2014;11:360–366

41 Patients: 14 LSCD, 27 BSCD

Freedom from ICD shocks: 48% (BSCD)

Significant ↓ ICD shocks: 90%

BSCD (48%) >> LSCD (30%)




Usually works for faster VTs

# Cardiac Sympathetic Denervation for Refractory Ventricular Arrhythmias

Between 2009 and 2016, 121 patients (age  $55 \pm 13$  years, 26% female, mean ejection fraction of  $30 \pm 13\%$ ) underwent left or bilateral CSD.

One-year freedom from sustained VT/ICD shock and ICD shock, transplant, and death were 58% and 50%, respectively.




**FIGURE 5** Pre-Procedural Characteristics Associated With VT/ICD Shock Recurrence After CSD

| Effect                    | VT/ICD Shock Recurrence | Hazard Ratio (95% CI) | P value |
|---------------------------|-------------------------|-----------------------|---------|
| > 1 VT morphology         |                         | 0.80 (0.36-1.74)      | 0.57    |
| # VT ablations            |                         | 0.86 (0.68-1.11)      | 0.24    |
| Female                    |                         | 0.95 (0.40-2.29)      | 0.92    |
| Age (years)               |                         | 0.99 (0.96-1.02)      | 0.42    |
| Left-side only            |                         | 1.03 (0.48-2.23)      | 0.94    |
| CKD                       |                         | 1.07 (0.45-2.53)      | 0.89    |
| Polymorphic VT            |                         | 1.11 (0.50-2.47)      | 0.80    |
| VT CL (20 ms)             |                         | 1.13 (1.04-1.22)      | 0.003   |
| > 1 AAD                   |                         | 1.29 (0.62-2.69)      | 0.50    |
| NYHA Functional Class II  |                         | 3.96 (0.87-18.1)      | 0.078   |
| NYHA Functional Class III |                         | 7.40 (1.58-34.7)      | 0.011   |
| NYHA Functional Class IV  |                         | 15.04 (2.72-83.2)     | 0.002   |


Advanced NYHA functional class and longer VT cycle length (CL) predicted recurrence of sustained VT and ICD shock. AAD = antiarrhythmic drug; CI = confidence interval; CKD = chronic kidney disease; other abbreviations as in [Figures 1, 3, and 4](#).

# Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry

Clin Res Cardiol (2016) 105:873–879




13 Patients. Four (31 %) and 11 (85 %) patients of these 13 patients were free from VA at 1 and 3 months.



**Fig. 3** Proportion of NYHA-class at baseline and after 1 month after renal denervation. *1M* 1-month follow-up

# Stereotactic Ablative Radiotherapy for the Treatment of Refractory Cardiac Ventricular Arrhythmia

Billy W. Loo, Jr, MD, PhD\*; Scott G. Soltys, MD\*; Lei Wang, PhD; Anthony Lo, MS; Benjamin P. Fahimian, PhD; Andrei Iagaru, MD; Linda Norton, RN, MSN; Xin Shan, BS, BAH; Edward Gardner, PhD; Thomas Fogarty, MD; Patrick Maguire, MD, PhD; Amin Al-Ahmad, MD; Paul Zei, MD, PhD



**Figure 1.** Stereotactic arrhythmia radioablation (STAR) treatment plan. **A**, Simulated cardiac ablation contours (dark blue); **B** and **C**, Final target volume (blue/yellow) treated with 25 Gy (Green isodose line) with higher dose (Red 29 Gy isodose line) centered within the mid-myocardial layer.


A STAR treatment plan of 25 Gy in a single outpatient treatment over 90 minutes to the 75% isodose line was designed, encompassing the inferoseptal, inferior, and inferolateral walls from base to apex.



High-energy heavy ions can deliver high radiation doses in small targets with reduced damage to the normal tissue compared to conventional X-rays.


**Mechanism of action:**

- (1) long-lasting vascular damage
- (2) fibrosis and
- (3) loss of polarity of targeted cardiomyocytes and wavy fibers with vacuolization.








# Noninvasive Cardiac Radiation for Ablation of VT


N Engl J Med 2017; 377:2325-2336








# Stereotactic Radiosurgery for Ablation of Ventricular Tachycardia



Ten patients underwent radiosurgical ablation (mean PTV, 22.15 ml; treatment duration, 68 min). After radiosurgery, four patients experienced nausea and one patient presented gradual progression of mitral regurgitation. During the follow-up (median 28 months), VT burden was reduced by 87.5% compared to baseline ( $P=0.012$ ) and three patients suffered non-arrhythmic deaths. After the blanking period, VT recurred in eight of ten patients.





**Presentation available at:**  
<https://www.arasharya.de/resources/>